Shopping Cart

Your shopping cart is currently empty

Ciprofibrate

Name: Ciprofibrate
Brand: TargetMol
SKU: T1264
Price: 42 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Catalog No. T1264Cas No. 52214-84-3

Alias Win35833

Ciprofibrate (Win35833) is a fibrate derivative with antilipidemic activity.

Ciprofibrate

Copy Product Info

😃Good

Purity: 99.63%

Catalog No. T1264Alias Win35833Cas No. 52214-84-3

Ciprofibrate (Win35833) is a fibrate derivative with antilipidemic activity.

Pack Size	Price	USA Warehouse	Global Warehouse
100 mg	$42	In Stock	In Stock
500 mg	$98	-	In Stock
1 mL x 10 mM (in DMSO)	$46	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.63%

Appearance:Solid

Color:White

Resource Download

COA HNMR LCMS

Product Introduction

Ciprofibrate AI Summary

Ciprofibrate exhibits a diverse range of bioactivities across multiple cellular and molecular assays. It demonstrates agonist activity at PPARalpha, particularly in human HepG2 cells with an EC50 of 900 nM and a fold change of 2.2 at 1.45 μg/mL, indicating potential in modulating PPARalpha signaling. In rat H4IIE cells, it shows an EC50 value of over 10,000 nM for gene induction via PPARalpha. Furthermore, it exhibits binding affinity towards rat recombinant L-FABP, achieving 85% activity at the low affinity site and 100% at the high affinity site via NMR. The compound also possesses antiproliferative effects against human PC3 cells, demonstrating a fold change (FC) value of 1.047 at 30 μM after 120 hours. Additionally, Ciprofibrate modulates multiple signals and pathways, including the Aryl hydrocarbon Receptor (AhR), Bloom's syndrome helicase, AmpC Beta-Lactamase, GCN5L2, and others, reflecting a broad spectrum of interaction. Ciprofibrate inhibits SARS-CoV-2 induced cytotoxicity in several cell lines, though with generally low potency, showing inhibitory values far above 20,000 nM, and demonstrates minimal inhibition of SARS-CoV-2 3CL-Pro protease at 20 μM. It also shows limited antiviral activity against SARS-CoV-2 in HRCE cells (hit score: 0.1099). Notably, Ciprofibrate displays inhibitory activity against human HDAC6 enzyme with modest percentages, suggesting potential as an HDAC6 inhibitor. It shows inhibitory effects on bile salt export pump (BSEP) in both rat and human models, reflecting its potential impact on bile acid transport. Additionally, it does not inhibit UGT1A10, BSEP, MRP3, or MRP4 significantly, as all IC50 values are greater than the upper threshold tested. Despite its multiple activities, Ciprofibrate has been flagged for moderate to severe hepatotoxicity according to Drug Induced Liver Injury (DILI) prediction systems and exhibits interactions with human recombinant enzymes UGT1A3 and UGT1A8 with activity levels around 84-86 pm/min/mg. Overall, Ciprofibrate demonstrates a varied bioactivity profile, with significant interactions in several biochemical and cellular contexts but often with relatively high effective concentrations or low potency..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	Ciprofibrate (Win35833) is a fibrate derivative with antilipidemic activity.
Synonyms	Win35833

Chemical Properties

Molecular Weight	289.15
Formula	C₁₃H₁₄Cl₂O₃
Cas No.	52214-84-3
Smiles	CC(C)(OC1=CC=C(C=C1)C1CC1(Cl)Cl)C(O)=O
Relative Density.	1.37 g/cm3

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

Ethanol: 54 mg/mL (186.75 mM), Sonication is recommended.

DMSO: 45 mg/mL (155.63 mM), Sonication is recommended.

H2O: < 1 mg/mL (insoluble or slightly soluble)

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.92 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO/Ethanol

	1mg	5mg	10mg	50mg
1 mM	3.4584 mL	17.2921 mL	34.5841 mL	172.9206 mL
5 mM	0.6917 mL	3.4584 mL	6.9168 mL	34.5841 mL
10 mM	0.3458 mL	1.7292 mL	3.4584 mL	17.2921 mL
20 mM	0.1729 mL	0.8646 mL	1.7292 mL	8.6460 mL
50 mM	0.0692 mL	0.3458 mL	0.6917 mL	3.4584 mL
100 mM	0.0346 mL	0.1729 mL	0.3458 mL	1.7292 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc